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Abstract
Purpose—Despite advances in medical technology, radiation dermatitis occurs in 95% of
patients receiving radiation therapy (RT) for cancer. Currently, there is no standard and effective
treatment for the prevention or control of radiation dermatitis. The goal of the study was to
determine the efficacy of oral curcumin, one of the biologically active components in turmeric, at
reducing radiation dermatitis severity (RDS) at the end of RT, using the RDS scale, compared to
placebo.
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Methods—This was a multisite, randomized, double-blinded, placebo-controlled trial of 686
breast cancer patients. Patients took four 500 mg capsules of placebo or curcumin three times daily
throughout their prescribed course of RT until one week post-RT.
Results—A total of 686 patients were included in the final analyses (87.5% white females, mean
age = 58). Linear mixed model analyses demonstrated that curcumin did not reduce radiation
dermatitis severity at the end of RT compared to placebo (B (95% CI) =0.044 (−0.101, 0.188),
p=0.552). Fewer curcumin patients with RDS > 3.0 suggested a trend toward reduced severity
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(7.4% vs. 12.9%, p=0.082). Patient-reported changes in pain, symptoms, and quality of life were
not statistically significant between arms.
Conclusions—Oral curcumin did not significantly reduce radiation dermatitis severity
compared to placebo. The skin rating variation and broad eligibility criteria could not account for
the undetectable therapeutic effect. An objective measure for radiation dermatitis severity and
further exploration for an effective treatment for radiation dermatitis is warranted.
Keywords
radiation therapy; dermatitis; curcumin; cancer; skin

INTRODUCTION
Author Manuscript

Ionizing radiation is a widely accepted form of cancer treatment. Approximately half of all
women diagnosed with breast cancer receive radiation therapy (RT) [41]. Conventional
fractionation RT involves 1.8–2.0 Gy per session for 25 to 35 sessions [2]. In recent years,
Canadian, or short-course, fractionation, has become more popular and involves 2.2–3.0 Gy
per session for 16 to 20 sessions [7, 13]. Despite advances in medical technology, radiationinduced skin reactions remain a problem. Intensity modulated RT (IMRT) should reduce the
prevalence of moist desquamation by providing a more uniform radiation dose; however it is
not the standard RT for breast cancer [9].
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Radiation dermatitis is one of the most common side effects experienced by patients with
breast cancer, head and neck cancer, lung cancer, or sarcoma, occurring in approximately
95% of patients [5, 22, 37]. The skin reactions range in severity from mild erythema to moist
desquamation. Approximately, 10% of patients experience moist desquamation and
ulceration [5, 22, 37]. Radiation dermatitis severity varies by individual and is influenced by
genetic factors, body area, as well as type and dose of radiation [5, 22, 37]. Important
consequences of radiation dermatitis include impaired quality of life and premature RT
interruption, which in turn, may impair local control of disease [20, 36]. Currently, there is
no effective treatment for the prevention or control of radiation dermatitis.
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Curcumin is one of the most widely studied nutraceuticals with over 10,000 publications in
PubMed and over 120 clinical trials (www.clinicaltrials.gov) [17]. Curcumin is an active
polyphenolic constituent of turmeric (Curcuma longa). [17]. Turmeric contains 2% to 6%
curcumin along with 60 other compounds that have antibiotic, anti-tumor, antiinflammatory, and antioxidant properties [35]. Curcumin and turmeric have been used to
treat acne, eczema, wound healing, and wrinkled skin [16, 24, 34, 44]. Modern research
supports curcumin’s antioxidant, anti-inflammatory, anti-cancer, anti-microbial, antiproliferative, and pro-apoptotic properties [14, 17, 25, 26, 28]. In 2006, Okunieff et al
published that oral curcumin reduced acute and chronic cutaneous radiation toxicity in mice
[32]. In 2013, we published a clinical trial of 30 breast cancer patients showing that 6.0
grams of oral curcumin daily during RT reduced the severity of radiation dermatitis and
presence of moist desquamation compared to placebo [38]. This study was a confirmatory,
multi-site, randomized, double-blinded, placebo-controlled clinical trial of 686 breast cancer
patients to assess the efficacy of oral curcumin to reduce radiation dermatitis severity.
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MATERIAL AND METHODS
Patients and Study Design
Eligible patients were adult females (≥18 years of age) diagnosed with non-inflammatory
breast cancer or carcinoma in situ, able to read and understand English, and prescribed
conventional or Canadian (i.e., short course) fractionated RT without concurrent
chemotherapy. Eligible patients included those who had: lumpectomy or mastectomy, breast
reconstruction, implants, expanders, chemotherapy prior to RT, hormone treatment, and/or
Herceptin. Exclusion criteria included: previous RT to the chest or breast area, partial breast
irradiations, anticoagulant therapy, epidermal growth factor receptor inhibitor (EGFRI)
therapy, history of radiosensitivity disorder or collagen vascular disease, unhealed surgical
wounds, and/or breast infections in the RT area.
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This study was a phase 2, randomized, double-blind, placebo-controlled trial conducted in
21 private practice oncology groups via the National Community Oncology Research
Program (NCORP) Research Base (a legacy NCI Community Clinical Oncology Program
(CCOP) Research Base) and NCORP affiliates nationwide. The study was conducted under
FDA IND 75,444 for Curcumin C3 Complex®, approved by the University of Rochester
Institutional Review Board and NCI Division of Cancer Prevention Office, and registered on
ClinicalTrials.gov Identifier: NCT01246973. Written informed consent was obtained from
each patient. Stratification included NCORP site and RT regimen (conventional vs.
Canadian). Within each site, a computer-generated random numbers table with block size of
four was used to randomly assign patients to curcumin or placebo in the ratio of 1:1. The
primary objective was to determine if oral curcumin reduced the severity of radiation
dermatitis in breast cancer patients during RT. Secondarily, we examined effects of curcumin
on moist desquamation, pain at RT site, skin-related quality of life, and severity of adverse
symptoms.
Study Medication
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Sabinsa Corporation (Payson, UT) manufactured the curcumin (Curcumin C3 Complex®)
and placebo capsules. The curcumin product was an opaque gelatin capsule filled with
yellow-colored granular powder consisting of 500mg of curcuminoids (450mg curcumin,
40mg dimethoxy curcumin, 10mg bisdemethoxy curcumin). The placebo product was the
same capsule filled with yellow-colored granular powder consisting of dicalcium phosphate
and a suitable food grade dye. Patients were dispensed one 84-count bottle of capsules (i.e.,
7 day supply of capsules) each week throughout their course of RT. All patients took four
capsules of curcumin or placebo three times daily with food (i.e., 6.0 g daily dose)
throughout their prescribed course of RT plus one week post-RT. Compliance was measured
by weekly pill counts prior to dispensing the new bottle of capsules.
Study Procedures and Measures
Eligibility screening and informed consent were performed prior to the start of RT. All
patients started their study medication on Day 1 of RT and continued until one week PostRT. “Standard care” for radiation dermatitis was allowed in all study arms. Patients were
assessed at baseline, weekly after every fifth RT session, at the end of RT (EndRT), and one
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week after RT (Post-RT). Patient assessments involved a clinical skin rating, digital imaging
of the skin changes, and the completion of three self-report questionnaires. The treating
radiation oncologist or trained study personnel performed the clinical skin ratings using the
Radiation Dermatitis Severity (RDS) scale [5, 37, 38]. The RDS scale is a 0 to 4 scale, with
0.5 increments, that evaluates radiation-induced color and texture changes in skin. The
primary outcome measure was the RDS score at EndRT. Secondary outcome measures
included the presence of moist desquamation at the EndRT, pain at RT site (McGill Pain
Questionnaire-Short Form (SF-MPQ), skin-related quality of life (Skindex-29), and adverse
symptoms (Symptom Inventory (SI)) [6, 38]. The SF-MPQ evaluated the severity and type
of pain (i.e., sensory, affective, or perceived pain) experienced by the patient at the RT site.
The SF-MPQ contains 11 sensory pain items, 4 affective pain items, and 1 perceived pain
item [38]. The sensory and affective pain items are rated on a 4-point scale anchored by 0
(“none”) and 4 (“severe”) with maximum subscales scores of 44 and 16, respectively. The
perceived pain item is rated on a 6-point scale anchored by 0 (“not present”) and 5
(“excruciating”). The maximum total SF-MPQ score is 66. The Skindex-29 questionnaire
measures the effects of a skin condition or disease on the patient’s quality of life [6]. In this
study, the Skindex-29 evaluated how radiation dermatitis altered a patient’s quality of life.
The questionnaire contains 30 items for health-related quality of life: emotions (10 items),
symptoms (7 items), and functioning (12 items). Patients rate how often a certain statement
describes them using a 5-point analog scale (e.g., never, rarely, sometimes, often, all the
time). The maximum composite Skindex-29 score is 145 with maximum subscale scores of
50 for emotion, 35 for symptoms, and 60 for functioning. The SI is a 17-item questionnaire,
adapted from the MD Anderson Symptom Inventory, used to monitor the severity of various
side effects of RT and/or study medication [38]. Patients rate the severity of symptoms (pain
at RT site, other pain, nausea, vomiting, distress, memory, appetite, diarrhea, skin problems,
sleep difficulties, fatigue, mood, breathing, urination, walking, relationships, activity, and
quality of life) using an 11-point scale anchored by 0 (“not present”) and 10 (“as bad as you
can imagine”).
Radiation Dermatitis Severity Ratings from Digital Images—Coordinators at each
site took digital images (i.e., photos) of the radiation-induced skin changes using a Canon
Powershot SD1300 IS Digital ELPH camera. The photos were uploaded onto a secure,
study-specific server at the NCORP Research Base. Using the photos from the End RT visit,
two reviewers (one Dermatologist and one Radiation Oncologist) rated radiation dermatitis
severity (RDS scale) and the presence of moist desquamation. Both reviewers were blinded
to the treatment arms and in-person RDS scores. The reviewers’ Photo RDS values were
averaged for final analysis.
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Statistical Analyses—Our published pilot trial showed a 0.65 decrease in RDS in the
curcumin arm with an upper 95% confidence bound of 1.1 on the standard deviation of 0.81
[38]. The upper confidence bound was used to infer that a sample of 254 patients per arm
would have 80% power to detect a 10% difference (a change in mean RDS score of 0.3) at
significance level of 0.05. Primary analysis included all randomized subjects who completed
baseline (N=686) and all other analyses included completed cases (N=578) (Figure 1). A
linear mixed model (LMM) was used to estimate the effect of the intervention on RDS at
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EndRT. Site was entered as a random effect, with Arm and RT regimen as fixed effects.
Restricted Maximum Likelihood estimation was used, and the Kenward-Roger method was
used for the F tests [27]. Under the plausible assumption that the missing value mechanism
was missing at random (MAR), we performed multiple imputation (MI) to assess the
magnitude of any biases due to missingness [31]. Chi-square tests were used to compare
proportions of patients with moist desquamation between each group. LMMs adjusting for
baseline were used to evaluate differences in pain at the RT site (MPQ-SF), quality of life
(Skindex-29), and other symptoms (SI) between arms. Forest plots were used to visualize
differences in mean change in severity (i.e., End RT-baseline) of pain descriptors (MPQ-SF)
and adverse symptoms (SI). In addition, comparative trajectories of MPQ-SF over time
(weeks) were assessed using LMMs and the addition of Week, and Week*Arm, and
Week*Arm*Stratification interaction. Due to skewness, the MPQ-SF values were log
transformed. LMM was also performed on the photo RDS ratings and results were compared
between the blinded reviewer ratings and the in-person ratings.
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RESULTS
Patient characteristics
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From February 2011 to February 2012, a total of 695 patients with breast cancer were
enrolled and randomized into one of two arms (Figure 1). Of these 695 patients, nine
patients withdrew prior to baseline and 686 patients continued forward with study
medication during RT. Of the 686 patients, 108 (15.7%) withdrew from the study and 578
patients completed the study. Reasons for non-completion included: unspecified reasons (63;
58.3%), diarrhea/nausea/vomiting (17; 15.7%), capsule size (6; 5.6%), and allergic reaction
(5; 4.6%) (Figure 1). The only reported adverse event involved Grade 2 abdominal pain and
vaginal infection, which was considered “unrelated” to study drug. Baseline characteristics
did not differ between arms, except for ER/PR (estrogen receptor/progesterone receptor)
status and chemotherapy prior to RT (Table 1). The curcumin arm had fewer patients with
ER-tumors and patients who had chemotherapy prior to RT (Table 1). Overall, the majority
of patients were white females (87.5%), with a mean age of 58 years, prescribed
conventional fractionation RT (89.1%). The total prescribed radiation dosage, maximum
radiation skin dosage, and total radiation treatment sessions were similar across treatment
arms (Table 1). Compliance did not differ between arms (96 % compliance = curcumin; vs.
97% compliance = placebo; p=0.251).
Severity of radiation dermatitis
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The most common locations for worst radiation dermatitis were the axillary region (placebo
= 44.2% and curcumin = 40.4%) and the inframammary fold (placebo = 44.6% and
curcumin = 42.6%). Of the 63 patients with moist desquamation, the inframammary fold
was the most common location (placebo = 49.2% and curcumin = 42.8%). The primary
analysis showed no significant difference in mean RDS score at EndRT between curcumin
and placebo (B (95%CI) = 0.044 (−0.101, 0.188), p=0.552). Site and RT regimen had highly
significant effects (p<0.001). In Figure 2a, boxplots show similar mean RDS scores across
treatment arms. The mosaic plot in Figure 2b shows a smaller proportion of RDS > 3.0 in
the curcumin arm, suggesting a trend toward reduced severity (7.4% (21/283) vs. 12.9%
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(38/295), p=0.082, monte-carlo estimate). The presence of moist desquamation (Figure 2c)
did not differ between arms (9.54% vs. 12.20%, OR (95% CI) = 0.763 (0.432–1.305,
p=0.324). No significant differences were observed for RDS scores (B (95% CI) = 0.109
(−0.226, 0.109, p=0.489) and moist desquamation (16.7% vs. 14.8%, OR (95% CI) = 1.15
(0.716–1.842), p=0.565) at 1 Week Post-RT. RDS scores ≥ 3.5 denote the presence of moist
desquamation; however, no correlation was observed between RDS ≥ 3.5 and moist
desquamation (Pearson r (95% CI) = 0.316 (0.056, 0.069), p=0.062). Only 23.2% of patients
with reported moist desquamation had an RDS score ≥ 3.5; whereas 69.6% of patients with
reported moist desquamation had RDS scores 2.0, 2.5 or 3.0. These results suggest no
beneficial curcumin effect, as well as inconsistencies with RDS ratings and reporting of
moist desquamation.

Author Manuscript

An exploratory aim of this study was to evaluate the ability of blinded reviewers to rate
radiation dermatitis severity from digital photos. Unfortunately, poor image quality led to a
low number of RDS ratings by blinded reviewers (N=519). The photo RDS values tended to
be higher with less NCORP variation than the corresponding site RDS values. The photo
ratings did not show any treatment arm effect for RDS (B (95% CI) = 0.036 (−0.086, 0.158),
p=0.563) or moist desquamation (15.29% vs. 16.67%; OR (95% CI) = 0.897 (0.554, 1.449);
p = 0.656).
Patient-reported Pain, Quality of Life, and Symptoms
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The SF-MPQ was used to assess pain at the RT site. The LMMs revealed no significant
differences in change of total, sensory, affective, or perceived pain from baseline to End RT
between arms (Table 2). Additionally, change of pain descriptors did not differ between arms
(Figure 3). Longitudinal analyses did not reveal any significant trajectory differences
between treatment arms. However, RT regimen did influence the longitudinal patterns of
affective pain. Over time, affective pain increased with Canadian fractionation, but
decreased with conventional fractionation. Furthermore, skin-related quality of life
(Skindex-29) did not differ between arms at End RT (Table 2). Similarly, mean change in
symptom severity, as measured by the SI, did not differ between arms (Figure 3). Overall,
patient-reported symptoms and quality of life did not differ between curcumin and placebo
arms.

DISCUSSION
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Despite a better understanding of the biological mediators of radiation skin toxicity, an
effective therapy has yet to be added to skin management guidelines. For over ten years, the
guidelines for management of skin during radiation recommend “washing with mild soap
and lukewarm water”, use of unscented, lanolin-free, water-based moisturizers, and
avoidance of sun exposure [5, 37]. Standard care for management of radiation dermatitis
varies greatly across cancer centers nationwide. We surveyed our 21 sites on standard care
for radiation dermatitis and none of the sites matched with each other. The list included: aloe
vera, Aquaphor, udder cream, Radiaplex®, corticosteroid creams, lidocaine cream,
Silvadine®, and antibiotic ointment. Topical agents are distributed to patients without
supportive evidence of therapeutic benefit [5, 11, 30]. Many studies have evaluated the use
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of topical corticosteroids with mixed results [5, 39]. Prophylactic steroid cream (0.1%
mometasone fuorate) and barrier film spray (3M Cavilon Barrier Film) was shown to
improve tolerance of radiotherapy in patients due to its ability to minimize inflammation and
protect skin barrier [42]. Recently, Ulff et al demonstrated that betamethasone-17-valerate
cream, a potent corticosteroid, was effective at preventing and reducing radiation dermatitis
in breast cancer patients [43]. However, the concern of skin integrity and adverse reactions
from prolonged treatment of local steroids has hindered its mainstream use. Di Franco et al
showed that prophylactic topical hyaluronate and steroid therapy combined with an Ixor®
oral therapy (consisting of Resveratrol, Lycopene, Vitamin C, and Anthocyanins) effectively
reduced the number of patients with high-grade radiation-induced skin toxicity [9]. Some
studies have shown increased wound healing with curcumin when combined with other
compounds, such as ginger and aloe vera [4, 12]. Undoubtedly, further studies are warranted
for an effective treatment for radiation dermatitis.
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Our previous study showed oral curcumin reduced the severity of radiation dermatitis and
moist desquamation in breast cancer patients. In contrast, the current study did not show a
significant difference between curcumin and placebo. There were several factors that
introduced variation that may have masked a beneficial effect. The eligibility criteria were
more inclusive in this current trial compared to the previous trial. Eligible patients included
those with breast reconstructions prior to RT and two different RT fractionation regimens.
We did stratify for RT regimen, but not breast reconstruction. Skin on a reconstructed breast
reacts differently than skin on an unaltered breast. After breast reconstruction, the skin is
more likely to burn due to its inability to dissipate heat [8]. The complication risks from RT
differ between autologous tissue reconstructions and implant/expander reconstructions [40,
41]. We could not use breast reconstruction as a factor in the statistical analyses due to lack
of documentation of which patients had reconstructions prior to RT. Overall, oral curcumin
did not demonstrate a detectable benefit for radiation dermatitis.
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Skin rater variation was the most contributing factor to our inconclusive results. First, two
RDS scores (i.e., 3.5 or 4.0) signify the presence of moist desquamation; however, close to
70% of patients with moist desquamation were given RDS scores of 2.0, 2.5 and 3.0,
suggesting inconsistencies in the RDS scale utilization. Secondly, the number of raters
performing skin assessments at each site was not limited to one rater per patient. Ideally, one
skin rater should assess one patient throughout the course of the study. However, sites did
not meet this ideal scenario. Inter-rater variation was evaluated because the number of skin
raters per patient per site was not recorded. For years, radiation dermatitis severity
assessments have utilized various subjective scales, including RDS, RTOG (Radiation
Therapy Oncology Group), and CTC (Common Toxicity Criteria) [5, 37]. Our RDS manual
containing pictures and descriptions was not enough training to minimize rating variation
across sites. Addition of a secondary subjective measure, such as the RTOG scale, would not
have reduced rating variation. Our study controlled for rater variation through the use of
blinded reviewers and digital photos. Unfortunately, insufficient numbers of quality images
lead to insignificant findings. However, our study did demonstrate the ability to document
radiation-induced skin changes during RT using digital images. The photo RDS values had
less variation than the in-person RDS values. Limiting the number of raters and extensive
rater training may have minimized the variation across sites.
Support Care Cancer. Author manuscript; available in PMC 2019 May 01.

Wolf et al.

Page 8

Author Manuscript
Author Manuscript

Clearly, there is substantial need for an objective and/or quantitative measure for radiation
dermatitis severity. Gonzalez Sanchis et al showed that real-time laser Doppler flowmetry
(LDF), which measure cutaneous microcirculation, is an accurate, objective measure for
radiation dermatitis severity [15]. The microcirculation index significantly increased from
baseline to end of RT and the skin changes were classified more objectively using LDF
compared to CTC scale [15]. Additionally, Esteva et al demonstrated the importance of
capturing skin reactions by digital photography [10]. Esteva et al developed a computational
method in which a computer, using a single convolutional neural network (CNN), can be
trained to classify and diagnose skin lesions using a large dataset of digital images [10]. The
study showed that the CNN performed on par with 21 board-certified dermatologists on
biopsy-proven clinical images. This computational method has not been applied to radiation
dermatitis; however Zenda et al has developed a picture atlas for grading of radiation
dermatitis for head-and-neck cancer patients [45]. LDF, digital images, and computer-aided
technology are promising solutions to the inconsistency and subjectivity of measuring
radiation dermatitis severity in clinical trials.
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For over a decade, curcumin has been evaluated for therapeutic potential due to its
antioxidant, anti-inflammatory, and anti-cancer properties. A systematic review concluded
that there is evidence that curcumin may benefit skin health, but further clinical studies are
required to evaluate efficacy and mechanism [44]. Recently, the clinical efficacy of curcumin
has been questioned due to its variable results in molecular drug screens [3, 18]. However,
44 published clinical trials have shown therapeutic effect [18]. Curcumin is limited by its
hydrophobic nature, poor water solubility, low bioavailability, and chemical instability. New
advances in pharmaceutical strategies, such as nanoencapsulation, may overcome these
limitations [1, 18, 21, 23]. Additionally, the isolation of curcumin from the other
constituents in turmeric may reduce its therapeutic potential. Curcumin’s demonstrated
therapeutic benefit and increased bioavailability when used as an adjunct drug in therapy
supports this argument [1, 4, 18, 21, 23, 33]. A future trial exploring turmeric or a combined
nutraceutical therapy for radiation dermatitis may yield positive results.
In conclusion, oral curcumin did not reduce radiation dermatitis severity compared to
placebo. High compliance rate and minimal adverse symptoms suggest that the oral
curcumin dose was well tolerated by patients. One critical finding from this study is the need
for an objective and/or quantitative measure for radiation dermatitis. A blood or skin
biomarker predictive of skin’s response to radiation therapy would be ideal; however LDF
technology is also promising and quantitative. All the limitations could be addressed in a
subsequent trial with a more stringent study design. Investigation of turmeric or combined
nutraceutical therapy for radiation dermatitis should be considered.
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Figure 1. Consort Diagram

This diagram documents the patient flow of the randomized patients in the trial.
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Figure 2. Radiation dermatitis severity (RDS) and moist desquamation did not differ between
treatment arms

Panel a: Boxplots portray the mean RDS scores at End RT by treatment arm. The mean and
range did not differ between treatment arms. Panel b: The mosaic plot shows fewer patients
in the curcumin arm with RDS > 3.0. Panel c: The mosaic plots shows similar proportions of
patients with moist desquamation in each treatment arm.
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Figure 3. Mean change scores for SI symptoms and SF-MPQ pain descriptors

Author Manuscript

The forest plot presents the mean severity change scores for pain descriptors on the SF-MPQ
and the symptoms on the SI. Red triangles are curcumin and blue squares are placebo. Errors
bars are 95% confidence intervals. QoL = quality of life.
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Patient Demographics
All
N = 686

Curcumin
N = 344 (50.1%)

Placebo
N = 342 (49.9%)

57.6 (0.4)

57.6 (0.6)

57.7 (0.5)

600 (87.5%)

307 (89.2%)

293 (85.7%)

Black/African American

59 (8.6%)

29 (8.4%)

30 (8.8%)

Multiracial

27 (3.9%)

8 (2.3%)

19 (5.6%)

Hispanic

13 (1.6%)

6 (1.7%)

7 (2.0%)

Non-Hispanic

672 (98%)

264 (76.7%)

237 (69.3%)

1 (0.1%)

1 (0.3%)

0 (0.0%)

29.8 (0.3)

29.5 (0.4)

30.0 (0.4)

Right

340 (49.6%)

169 (49.1%)

171 (50.0%)

Left

333 (48.5%)

169 (49.1%)

164 (48.0%)

13 (1.9%)

6 (1.7%)

7 (2.0%)

Age
Mean (SE)
Race
White/Caucasian

Ethnicity

Author Manuscript

Unknown
BMI
Mean (SE)
Tumor Location

Bilateral
Tumor Stage

Author Manuscript

0

97 (17.4%)

48 (14.0%)

49 (14.3%)

I

235 (42.2%)

125 (36.3%)

110 (32.2%)

II

141 (25.3%)

69 (20.0%)

72 (21.1%)

III

75 (13.5%)

36 (10.5%)

39 (11.4%)

IV

6 (1.1%)

4 (1.2%)

2 (0.6%)

More than One Stage

3 (0.4%)

1 (0.3%)

2 (0.6%)

ER+/PR+

501 (73.6%)

264 (76.7%)

237 (69.3%)

ER+/PR−

9 (1.3%)

6 (1.7%)

3 (0.9%)

ER−/PR+

68 (10.0%)

27 (7.8%)

41 (12.0%)

ER−/PR−

102 (15.0%)

42 (12.2%)

60 (17.5%)

1 (0.1%)

1 (0.3%)

0 (0.0%)

Positive

89 (14.8%)

40 (11.6%)

49 (14.3%)

Negative

512 (85.2%)

262 (76.2%)

250 (73.1%)

Yes

283 (41.3%)

128 (37.2%)

155 (45.3%)

No

396 (57.7%)

212 (61.6%)

184 (53.8%)

ER/PR Status*

ER+/PR+ & ER−/PR−
Her2/Neu Status

Author Manuscript

Previous Chemotherapy**
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All
N = 686

Curcumin
N = 344 (50.1%)

Placebo
N = 342 (49.9%)

Conventional Fractionation

611 (89.1%)

307 (89.2%)

304 (88.9%)

Canadian Fractionation

75 (10.9%)

37 (10.8%)

38 (11.1%)

Prescribed Whole Breast Dose (SE)

48.34 (0.14)

48.43 (0.19)

48.24 (0.19)

Whole Breast Maximum Skin Dose (SE)

51.10 (0.26)

51.20 (0.37)

51.02 (0.37)

Total RT Sessions (SE)

29.89 (0.23)

30.18 (0.32)

29.61 (0.32)

Yes

407 (59.3%)

192 (55.8%)

215 (62.9%)

No

277 (40.4%)

150 (43.6%

127 (37.1%)

Yes

148 (21.6%)

73 (21.2%)

75 (21.9%)

No

535 (78.0%)

269 (78.2%)

266 (77.8%)

Radiation Therapy Stratification

Mean Radiation Dose (Gy)

Expected RT Skin Problem

Expected RT Pain

Author Manuscript

*

Curcumin arm had significantly fewer patients with ER- tumors (p=0.033).

**

Curcumin arm had significantly fewer patients with previous chemotherapy (p=0.040).
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LMM results for SF-MPQ & Skindex-29
Effect Estimate (B)

95% CI

p-value

MPQ-SF Scales
Sensory

0.007

−0.023, 0.034

0.714

Affective

0.034

−0.003, 0.071

0.068

Perceived Pain

0.012

−0.021, 0.045

0.481

Total MPQ-SF

0.791

−0.572, 2.154

0.255

Emotion

0.911

−0.361, 0.021

0.286

Symptom

0.654

−2.310, 3.617

0.665

Composite

0.741

−0.394, 0.021

0.407

Worry

0.281

−2.910, 3.473

0.863

Skindex-29 Scales

Author Manuscript
Author Manuscript
Author Manuscript

Support Care Cancer. Author manuscript; available in PMC 2019 May 01.

